Small Interfering RNA SiRNA Market to Hit USD 964.17 Million by 2030

Small Interfering RNA SiRNA Market to Hit USD 964.17 Million by 2030: Cognitive Market Research

Small Interfering RNA (SiRNA) Market size is projected to be $964.17 Million by 2030 growing at a CAGR of 8.6% from 2023 to 2030, as per a recent study published by Cognitive Market Research. Companies operating in Small Interfering RNA (SiRNA) market are focusing on strategic collaboration to meet customer need for a simplified, faster development process. For instance, Arrowhead and Horizon have entered into a USD 700 Million deal to develop an RNAi drug.

Major findings during the study of the Small Interfering RNA (SiRNA) Market:

  • Liposome-based systemic therapy is used to encapsulate different types of genetic payloads, including siRNA, mRNA, and saRNA as it is geared towards encapsulating a wide variety of nucleic acids. They are primarily composed of cationic lipids along with some other lipid ingredients. All these ingredients, when combined provide a stealth effect to the drug product as it circulates within the body
  • In terms of therapeutics, the Cancer segment dominates the Small Interfering RNA (SiRNA) market. This can be attributed to siRNA being produced from the long dsRNAs and small hairpin RNAs with the help of enzyme dicer. It prevents the process of translation by degrading mRNA. This function of the siRNA is seen as one of the most critical therapeutic tools for the treatment of various genetic disorders, including cancer
  • North America has dominated the SiRNA market in 2022 owing to the availability of strong R&D activities in the U.S. For instance, in March 2020, AstraZeneca collaborated with Silence Therapeutics to discover, develop and commercialize siRNA therapeutics
  • APAC region will show a lucrative growth rate in coming years, which is due to the rise in the funding activities for research and development. For instance, in 2021, Silence Therapeutics PLC entered the Chinese market through a partnering deal with Hansoh Pharmaceutical Group Co. Ltd. that involves developing short interfering RNA (siRNA) drugs against three undisclosed targets. Further, the high growth can be attributed to Sino-Korean tie-up in siRNA therapeutics in 2021


Read Full Market Analysis Small Interfering RNA siRNA: by Product Type (Liposome Based Systemic Therapy, Nanoparticle-Based Systemic Therapy, Others); by Therapeutics  (Cancer, AIDS, Alzheimer's Disease, Parkinson's Disease, Others) by Application (Hospital, Research Institutions, Academic Institutions, Pharmaceutical and Biotechnology, Companies, Others); by Region (North America, Europe, Asia Pacific, Latin America and Middle East, and Africa) Global Industry Analysis, COVID-19 Impact, and Industry Forecast, 2018-2030


Global Small Interfering RNA (SiRNA) Market


Global Revenue (USD Million)


CAGR (2023 to 2030)

8.6 %

Key Product Type Share

Liposome Based Systemic Therapy:52.01%

Key Therapeutics Share


Key Application Share

Research Institutions:43.07%

Key Regional Share

North America:36.37%


Small Interfering RNA (SiRNA) Market Growth and Trends

Cell and gene therapy R&D partnerships are increasing in proportion of all partnerships. It has been analyzed that cell-based immuno-oncology therapies are an incredibly active area of clinical development, representing nearly 60% of clinical trials in cancer treatment. A growing understanding of RNA functions and their vital role in various diseases has promoted its potential therapeutic usage. Recently, therapeutics have shown a vast diversification from small-molecule drugs. siRNA therapeutics have captured the interest of researchers. For instance, Arrowhead Pharmaceuticals and Horizon Therapeutics have entered a global partnership and license agreement to develop the former's ribonucleic acid interference (RNAi) therapeutic. As per this deal, Arrowhead has to carry out all the activities related to the therapeutic's preclinical development. Horizon will obtain an exclusive global license for ARO-XDH and will oversee the clinical development and marketing of the therapeutic.

Moreover, the clinical application of siRNA to "silence" the expression of specific malignant genes can be used to treat both genetic and acquired diseases. Hence, Sanofi and Alnylam Pharmaceuticals, Inc. have announced a strategic restructuring of their RNAi therapeutics alliance to streamline and optimize the development and commercialization of specific products for the treatment of rare genetic diseases.

With four agents already approved by FDA, many others are in the advanced stages of the drug development pipeline. This will stimulate siRNA drugs to become a standard modality of pharmacotherapy.

Read the Full Report with the Table of Contents and Consult with Author:


Small Interfering RNA (SiRNA) Market Report Scope

Small Interfering RNA (SiRNA) Market - Product Type Outlook (Revenue, USD Million, 2018–2030)

  • Liposome Based Systemic Therapy
  • Nanoparticle-Based Systemic Therapy
  • Others

Small Interfering RNA (SiRNA) Market - Therapeutics Outlook (Revenue, USD Million, 2018–2030)

  • Cancer
  • AIDS
  • Alzheimer's Disease
  • Parkinson's Disease
  • Others

Small Interfering RNA (SiRNA) Market - Application Outlook (Revenue, USD Million, 2018–2030)

  • Hospital
  • Research Institutions
  • Academic Institutions
  • Pharmaceutical and Biotechnology Companies
  • Others

By Regions

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, France, UK, Italy, Spain, Russia, Rest of Europe)
  • Asia Pacific (China, Japan, India, South Korea, Australia, Southeast Asia, Rest of APAC)
  • Latin America (Brazil, Argentina, Columbia, Rest of Latin America)
  • Middle East & Africa (GCC, Saudi Arabia, Turkey, Egypt, Rest of MEA)

List of Key Companies

  • GE
  • Thermo Scientific
  • Arbutus Biopharma
  • Sanofi Genzyme
  • Sylentis
  • Arrowhead Research
  • AInylam Pharmaceuticals
  • Genecon Biotechnologies
  • Silent Therapeutics
  • Horizon Discovery
  • OPKO Health
  • Others


Related Reports to Small Interfering RNA (SiRNA) Market:

Global mRNA Vaccine market is expected to hit USD 97.51 billion by 2030, growing at a CAGR of 6.85%mRNA is a biological substance given in a series of shots to protect the body from developing a disease. Recently, emerging and re-emerging infectious diseases are posing a public health threat across the globe. This era has witnessed a wave of severe contagious disease outbreaks, which have devastatingly impacted lives and livelihoods around the globe. Further, environmental changes, caused by intensive industry development due to globalization have impacted human health. It has stimulated a high prevalence of infectious diseases, which boosts the market of mRNA vaccines market.

The global gene therapy market is projected to reach USD19.08 billion by 2030, growing at a CAGR of 18.97%Gene therapy is a kind of medical approach that treats or prevents disease by correcting the underlying genetic problem. It thus allows doctors to treat a disorder by altering a person's genetic makeup instead of using drugs or surgery.  The increase in research activities in the healthcare sector results in a surge of the gene therapy market.

Other Related Reports:

  • Global DNA Sequencing Market to reach USD 43.36 Billion by 2030, growing at an impressive CAGR of 18.3%
  • Global MicroRNA (miRNA) Market to be worth USD 3.60 Billion by 2030 and is expected to reach a CAGR of 15.8%
  • Global RNA Therapeutics Market to hit USD 26.34 Billion by 2030 and is expected to reach a CAGR of 16.5%


Explore Other Healthcare Industry Reports Published by Cognitive Market Research